Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive‐enhancing medications
Movement Disorders2018Vol. 33(11), pp. 1769–1776
Citations Over TimeTop 10% of 2018 papers
Alberto J. Espay, Michael T. Guskey, James C. Norton, Bruce Coate, Joaquín A. Vizcarra, Clive Ballard, Stewart A. Factor, Joseph H. Friedman, Anthony E. Lang, Niccole J. Larsen, Candace Andersson, Doral Fredericks, Daniel Weintraub
Abstract
The antipsychotic effect of pimavanserin is robust in PD patients with cognitive impairment and may be enhanced by concomitant cognitive-enhancing medication use. Future prospective studies are needed to confirm these preliminary findings. © 2018 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.
Related Papers
- → Concomitant Persistent Pain in Classical Trigeminal Neuralgia – Evidence for Different Subtypes(2014)124 cited
- → Hemolytic uremic syndrome in families ? an argentinian experience(1996)3 cited
- → 389: Impact of concomitant operative procedures on left ventricular assist device implantation outcomes(2007)
- Concomitant relationship and clinical significance of the arteries and veins of the hand(2000)
- [Concomitant disorders among the mentally retarded].(1990)